ESMO TAT 2021 | Subtypes of EGFR- and HER2-mutant metastatic NSCLC influence response to ICIs

Adrian Sacher, MD, MMSc, FRCPC, Princess Margaret Cancer Centre, Toronto, ON, discusses the suitability of immunotherapy for tumors with targetable mutations. Patients with rarer EGFR or HER2 mutations seemed to do better than patients with more common EGFR or HER2 mutations when treated with immune checkpoint inhibitors (ICIs), consistent with previous studies on the same topic. Overall each individual targetable genomic alteration should be taken into account when evaluating the suitability of immunotherapy. This interview took place during the ESMO TAT 2021 conference.